QIAGEN N.V.
QGEN Real Time Price USDRecent trades of QGEN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in QGEN holdings by institutional investors
Quarterly net insider trading by QGEN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
QGEN Estimated quarterly lobbying spending
QGEN Revenue by Segment or Geography
New QGEN patent grants
-
Patent Title: Reagent cartridge Jan. 31, 2023
-
Patent Title: Flow cell holder Aug. 23, 2022
-
Patent Title: Flow cell holder Aug. 23, 2022
-
Patent Title: Sample processing method and sample processing cartridge Jun. 12, 2018
-
Patent Title: Preparation of silica particles Apr. 10, 2018
-
Patent Title: Quantification of rna Mar. 13, 2018
-
Patent Title: Tube for chemical, biological or biotechnology matter, tube arrangement, carrier for use in a tube arrangement, use of a tube, and method for forming a tube Mar. 13, 2018
-
Patent Title: Apparatus for processing biological material Feb. 27, 2018
-
Patent Title: Isolation of nucleic acid from stool samples and other biological materials which are rich in inhibitors Feb. 13, 2018
-
Patent Title: Method for processing a fluid and fluid processing device Dec. 26, 2017
-
Patent Title: Control for diagnostic assay Nov. 21, 2017
-
Patent Title: Method for isolating nucleic acids Nov. 07, 2017
-
Patent Title: Method for isolating short-chain nucleic acids Oct. 17, 2017
-
Patent Title: Composition and methods for rt-pcr comprising an anionic polymer Sep. 12, 2017
-
Patent Title: Fluid processing tube capable of being used in optical analysis and method for optically analyzing a fluid Aug. 22, 2017
-
Patent Title: Method for isolating nucleic acids Jul. 04, 2017
-
Patent Title: Method for activating a nucleic acid for a polymerase reaction Jun. 20, 2017
-
Patent Title: Nucleic acid purification method May. 30, 2017
-
Patent Title: Apparatus for processing biological material May. 23, 2017
-
Patent Title: Method for purifying a target nucleic acid Apr. 18, 2017
-
Patent Title: Lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids Apr. 11, 2017
-
Patent Title: Reaction mixtures for forming cdna from an rna template Apr. 04, 2017
-
Patent Title: Quantification of nucleic acids Mar. 07, 2017
-
Patent Title: Preparation and amplification of nucleic acids by means of magnetic particles Feb. 21, 2017
-
Patent Title: Layering for separating particles Dec. 13, 2016
-
Patent Title: Method for extracting nucleic acid from blood Nov. 29, 2016
-
Patent Title: Nucleic acid amplification Nov. 08, 2016
-
Patent Title: Method of isolating purified rna with reduced dna contaminations Nov. 08, 2016
-
Patent Title: Extraction of nucleic acids from wax-embedded samples Oct. 04, 2016
-
Patent Title: Method and device for isolating and purifying double-stranded nucleic acids Oct. 04, 2016
-
Patent Title: Modified sina Aug. 23, 2016
-
Patent Title: Process for parallel isolation and/or purification of rna and dna Aug. 23, 2016
-
Patent Title: Method for the isolation of nucleic acids Aug. 09, 2016
-
Patent Title: Method of loading a crystallization device May. 31, 2016
-
Patent Title: Method for quantifying human dna using an internal control May. 03, 2016
-
Patent Title: Method for polymerase chain reactions with use of a dna polymerase with proofreading properties Apr. 12, 2016
-
Patent Title: Method for quantifying human dna Mar. 22, 2016
-
Patent Title: Method and apparatus for the simultaneous, automated decomposition of a plurality of biological samples Jan. 26, 2016
-
Patent Title: Sample receptacle Jan. 26, 2016
-
Patent Title: Method of polyadenylation and cdna synthesis in a single reaction Dec. 22, 2015
-
Patent Title: Method for isolating and purifying nucleic acids Oct. 20, 2015
-
Patent Title: Oligonucleotides comprising a label associated through a linker Oct. 06, 2015
-
Patent Title: Method for isothermal amplification of nucleic acids Sep. 15, 2015
-
Patent Title: Nucleic acid purification method Aug. 11, 2015
-
Patent Title: Method and kit for processing wax-embedded biological samples Aug. 04, 2015
-
Patent Title: Primers for helicase dependent amplification and their methods of use Jul. 07, 2015
-
Patent Title: Method for detecting and/or quantifying human dna May. 26, 2015
-
Patent Title: Monolithic-shaped bodies for purifying and separating biopolymers Apr. 28, 2015
-
Patent Title: Method for selectively enriching and isolating microbial and optionally additional viral nucleic acids Apr. 21, 2015
-
Patent Title: Helicase dependent isothermal amplification using nicking enzymes Apr. 14, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to QGEN from public contracts
Recent insights relating to QGEN
Recent picks made for QGEN stock on CNBC
ETFs with the largest estimated holdings in QGEN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $QGEN stock a Buy, Sell, or Hold?
- What is the price target for $QGEN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $QGEN stock?
- Who owns the most shares of $QGEN stock?
- What funds own $QGEN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view QGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).